A Predictive Model of 2yDFS During MR-Guided RT Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients.

MRgRT delta radiomics neoadjuvant chemoradiotherapy predictive model rectal cancer

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 08 12 2021
accepted: 31 01 2022
entrez: 14 3 2022
pubmed: 15 3 2022
medline: 15 3 2022
Statut: epublish

Résumé

Distant metastasis is the main cause of treatment failure in locally advanced rectal cancer (LARC) patients, despite the recent improvement in treatment strategies. This study aims to evaluate the "delta radiomics" approach in patients undergoing neoadjuvant chemoradiotherapy (nCRT) treated with 0.35-T magnetic resonance-guided radiotherapy (MRgRT), developing a logistic regression model able to predict 2-year disease-free-survival (2yDFS). Patients affected by LARC were enrolled in this multi-institutional study. A predictive model of 2yDFS was developed taking into account both clinical and radiomics variables. Gross tumour volume (GTV) was delineated on the magnetic resonance (MR) images acquired during MRgRT, and 1,067 radiomic features (RF) were extracted using the MODDICOM platform. The performance of RF in predicting 2yDFS was investigated in terms of the Wilcoxon-Mann-Whitney test and area under receiver operating characteristic (ROC) curve (AUC). 48 patients have been retrospectively enrolled, with 8 patients (16.7%) developing distant metastases at the 2-year follow-up. A total of 1,099 variables (1,067 RF and 32 clinical variables) were evaluated in two different models: radiomics and radiomics/clinical. The best-performing 2yDFS predictive model was a delta radiomics one, based on the variation in terms of area/surface ratio between biologically effective doses (BED) at 54 Gy and simulation (AUC of 0.92). The results of this study suggest a promising role of delta radiomics analysis on 0.35-T MR images in predicting 2yDFS for LARC patients. Further analyses including larger cohorts of patients and an external validation are needed to confirm these preliminary results.

Identifiants

pubmed: 35280799
doi: 10.3389/fonc.2022.831712
pmc: PMC8907443
doi:

Types de publication

Journal Article

Langues

eng

Pagination

831712

Informations de copyright

Copyright © 2022 Chiloiro, Boldrini, Preziosi, Cusumano, Yadav, Romano, Placidi, Lenkowicz, Dinapoli, Bassetti, Gambacorta and Valentini.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Cancer Med. 2020 Jan;9(1):361-373
pubmed: 31693304
Colorectal Dis. 2016 Mar;18(3):234-46
pubmed: 26531759
Radiother Oncol. 2015 Mar;114(3):302-9
pubmed: 25716096
Eur J Cancer. 2011 May;47(7):990-6
pubmed: 21257306
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Annu Int Conf IEEE Eng Med Biol Soc. 2015 Aug;2015:771-4
pubmed: 26736376
Eur J Cancer. 2016 Aug;63:11-24
pubmed: 27254838
N Engl J Med. 2006 Sep 14;355(11):1114-23
pubmed: 16971718
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60
pubmed: 15936556
Strahlenther Onkol. 2012 Jan;188(1):97-9
pubmed: 22234506
J Clin Oncol. 2011 Aug 10;29(23):3163-72
pubmed: 21747092
Phys Med. 2021 Apr;84:186-191
pubmed: 33901863
Clin Transl Radiat Oncol. 2019 Jul 03;19:12-16
pubmed: 31334366
Radiother Oncol. 2019 May;134:110-118
pubmed: 31005204
Lancet Oncol. 2021 May;22(5):702-715
pubmed: 33862000
Lancet Oncol. 2020 May;21(5):e252-e264
pubmed: 32359501
Clin Transl Radiat Oncol. 2021 Feb 25;28:1-9
pubmed: 33732909
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Clin Transl Radiat Oncol. 2019 Apr 12;18:80-86
pubmed: 31341981
BMC Cancer. 2015 Oct 23;15:767
pubmed: 26497495
Biom J. 2008 Jun;50(3):419-30
pubmed: 18435502
Diagnostics (Basel). 2021 Jan 05;11(1):
pubmed: 33466307
J Magn Reson Imaging. 2018 Feb 13;:
pubmed: 29437271
Front Oncol. 2020 Dec 03;10:595012
pubmed: 33344243
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Radiol Med. 2021 Mar;126(3):421-429
pubmed: 32833198
World J Gastroenterol. 2020 Sep 7;26(33):5008-5021
pubmed: 32952346
J Clin Oncol. 2011 Dec 10;29(35):4633-40
pubmed: 22067400
Front Oncol. 2021 Dec 09;11:774413
pubmed: 34956893
Acad Radiol. 2021 Nov;28 Suppl 1:S95-S104
pubmed: 33189550
J Surg Oncol. 2017 Mar;115(4):462-469
pubmed: 28105657
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1347-1356
pubmed: 32758641
Radiol Med. 2019 Feb;124(2):145-153
pubmed: 30374650
Nat Commun. 2020 Aug 27;11(1):4308
pubmed: 32855399
Lancet Oncol. 2011 Jun;12(6):575-82
pubmed: 21596621
Radiother Oncol. 2018 Sep;128(3):564-568
pubmed: 30196982
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
Radiother Oncol. 2016 Aug;120(2):195-201
pubmed: 27528121
Br J Surg. 2012 Jul;99(7):918-28
pubmed: 22362002
Eur Radiol. 2018 Apr;28(4):1465-1475
pubmed: 29043428
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Radiother Oncol. 2008 Dec;89(3):347-52
pubmed: 18762345

Auteurs

Giuditta Chiloiro (G)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Luca Boldrini (L)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Francesco Preziosi (F)

Dipartimento Universitario di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.

Davide Cusumano (D)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Poonam Yadav (P)

Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.

Angela Romano (A)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Lorenzo Placidi (L)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Jacopo Lenkowicz (J)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Nicola Dinapoli (N)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Michael F Bassetti (MF)

Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.

Maria Antonietta Gambacorta (MA)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Vincenzo Valentini (V)

Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Classifications MeSH